Article ISI SCOPUS
Frontiers in Cardiovascular Medicine  (2022)

Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report

Ramos G.E.; Caglevic C.; Bulnes J.F.; Panay S.E.; Zapata M.I.; Daniele A.J.; Rodriguez M.E.

Keywords: nsclc, egfr mutation, Takotsubo (stress) cardiomyopathy, Afatinib, tyrosine kinase inhibition

Abstract

Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.

Más información

Título según WOS: Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
Título según SCOPUS: Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report
Título de la Revista: Frontiers in Cardiovascular Medicine
Volumen: 9
Editorial: Frontiers Media S. A.
Fecha de publicación: 2022
Idioma: English
DOI:

10.3389/fcvm.2022.1060813
Notas: ISI, SCOPUS